news & events
ysios portfolio archive
17.03.16
TiGenix Presents 24 Week Results of its Cx601 Phase III Trial at ECCO 2016
09.03.16
”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital
08.03.16
Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial
07.03.16
TiGenix announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn’s disease patients
03.03.16
TiGenix submits MAA to EMA for Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients
